Sales of 7,868 million yen for Q1, a quarterly high; operating income of 521 million yen, returning to profit. For the full-year 2027, revisions to the previously announced earnings guidance have been disclosed. Overseas orders surged, and the NR profit improvement was driven by revenue recognition from late-stage projects and foreign exchange gains.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2395-20260805-01.pdf","jir_short_summary":"Sales of 7,868 million yen for Q1, a quarterly high; operating income of 521 million yen, returning to profit. For the full-year 2027, revisions to the previously announced earnings guidance have been disclosed. Overseas orders surged, and the NR profit improvement was driven by revenue recognition from late-stage projects and foreign exchange gains.","jir_summary":"### Performance overview\nIn this first quarter, sales reached a record high led by the CRO business. Quarter-on-quarter sales increased and operating income turned to profitability. The commercialization delay of Satsuma\u2019s intranasal drug contributed to some lift in operating income, and foreign exchange gains also contributed. Equity-method income from PPD also supported overall profitability.\n\n### Segment trends and investment\/development\nCRO: sales 7,537 million yen, operating income 1,538 million yen. TR: sales 59 million yen, operating loss 966 million yen. Medipolis: sales 237 million yen, operating income 16 million yen. Overseas order intake share increased and total orders on hand rose. As for future investments, EU experimental facilities expansion etc. continues.","jir_financial_highlights":"Sales: 7,868\u767e\u4e07\u5186 (YoY +21.5\uff05)\nOperating income: 521\u767e\u4e07\u5186 (Improved from \u25b3340\u767e\u4e07\u5186 in the previous Q1)\nOrdinary income: 1,433\u767e\u4e07\u5186 (YoY +917\u767e\u4e07\u5186 (+177.9\uff05))\nNet income attributable to owners of parent: 1,064\u767e\u4e07\u5186 (YoY +803\u767e\u4e07\u5186 (+308.6\uff05))\nNet assets per share: 1,002.40\u5186 (Compared to prior year)","jir_category":"","jir_hashtags":"#ShinNipponScience, #financial_summary, #JapanStocks","jir_key_figures":"Sales: 7,868\u767e\u4e07\u5186\nOperating income: 521\u767e\u4e07\u5186\nOrdinary income: 1,433\u767e\u4e07\u5186","jir_meta_title":"Shin Nippon Science Co., Ltd. 1Q 2027 Earnings Summary | Sales 7,868 million yen, Operating income 521 million yen","jir_meta_description":"Key points of Shin Nippon Science's Q1 FY2027 earnings. Sales reached a record high, operating income turned positive, ordinary income 1,433 million yen, net income attributable to owners of parent 1,064 million yen.","jir_og_title":"Shin Nippon Science | 1Q 2027 Earnings Highlights","jir_og_description":"Shin Nippon Science's Q1 earnings amounted to 7,868 million yen in sales and 521 million yen in operating income. Discussing future outlook and segment trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q4\\\",\\\"2027Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales\\\",\\\"data\\\":[6477,7868]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q4\\\",\\\"2027Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[-340,521]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Sales\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"CRO\\\",\\\"TR\\\",\\\"Medipolis\\\",\\\"US Real Estate\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales\\\",\\\"data\\\":[7537,59,237,49]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Segment Profit Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"CRO\\\",\\\"TR\\\",\\\"Medipolis\\\",\\\"US Real Estate\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Profit margin\\\",\\\"data\\\":[20.4, -?, 6.7, -?]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"columns\\\":[\\\"Period\\\",\\\"Sales\\\",\\\"Operating income\\\",\\\"Ordinary income\\\"],\\\"rows\\\":[[\\\"Q1\\\",\\\"7868\\\",\\\"521\\\",\\\"1433\\\"]]},\\\"options\\\":{}}\"}]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-94523","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n